Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revolution Medicines reports positive clinical progress and financial stability

Revolution Medicines made significant strides in clinical development and financial stability, despite anticipating increased expenses in 2023
Confidence in the efficacy and tolerability of RMC-6236 and RMC-6291, with a focus on optimizing dosing strategies for future development
Challenges include financial projections for 2023, patient evaluation discrepancies, and the need for more data on dose levels and response rates
Opportunities lie in exploring intermittent dosing, discussing specific response rates, and further data collection for dose optimization

Revolution Medicines reports promising antitumor activity and strengthens financial position

Revolution Medicines showcased progress in their innovative inhibitor programs, bolstered by a successful equity offering. While facing competition and addressing analyst concerns, the company is poised to deliver significant clinical updates and expand their data set for future growth.

Revolution Medicines reports Q2 progress, acquires EQRx for growth

Revolution Medicines showcased financial strength, pipeline progress, and strategic acquisitions, positioning the company for future growth.
While facing challenges in managing expenses and advancing drug candidates, opportunities in pivotal trials and partnerships present avenues for success.
Overall, Revolution Medicines remains optimistic about its clinical developments and financial stability, signaling a promising trajectory in the biopharmaceutical sector.

Revolution Medicines reports strong Q3 results and strategic investment plans

Revolution Medicines showcased promising drug results, bolstered its financial position through an acquisition, and emphasized strategic spending for value creation. Analyst inquiries highlighted the importance of clear communication and effective financial planning for future success.

Revolution Medicines reports robust 2023 performance and strategic growth

Revolution Medicines showcased strong financial performance and progress in 2023.
The company faces challenges in revenue and net loss but sees opportunities in global partnerships and drug combinations.
Strategic priorities for 2024 focus on advancing RAS inhibitors and expanding reach.
Overall, Revolution Medicines is positioned for growth despite facing financial and developmental challenges.

Revolution Medicines advances pivotal cancer trials amidst financial projections

Revolution Medicines is well-capitalized and focused on advancing key therapies.
Facing financial challenges but exploring partnerships and business growth.
Opportunities lie in expanding RMC-6236's efficacy and exploring new indications.

Revolution Medicines excels in Q2 with RAS(ON) inhibitor progress

Revolution Medicines' Q2 performance reflects strong advancements in oncology treatments, supported by a solid financial position and strategic leadership decisions.
While facing challenges in trial execution and financial management, the company's focus on innovation and growth presents significant opportunities for expansion.
Overall, Revolution Medicines is well-positioned to capitalize on the potential of its RAS(ON) inhibitor pipeline and drive future success in the biopharmaceutical industry.

Revolution Medicines reports Q3 loss but shows promise in cancer treatments

Revolution Medicines showcased progress in cancer treatments despite a net loss in Q3 2024. Strong cash reserves, promising data, and strategic collaborations position the company for future growth. Clear communication on financial strategies and upcoming milestones will be crucial for investor confidence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in Session

Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON)

Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

REDWOOD CITY, Calif., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 22nd Annual Global Investment Conference. The conference, which will take place September 14-16, 2020, is being conducted with a virtual format.

Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Company’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event Company’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event

Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference

Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

Revolution Medicines (RVMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Revolution Medicines (RVMD) Catches Eye: Stock Jumps 10.2%

REDWOOD CITY, Calif., July  08, 2020  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be approximately $156.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on July 13, 2020, subject to customary closing conditions.

Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock

Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus Newly Discovered Natural Product and Designed Analogues Bind to Human Protein that is Exploited by the SARS-CoV-2 Virus

Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus

REDWOOD CITY, Calif., June  22, 2020  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today provided a research and development (R&D) update regarding the company's innovative portfolio directed against RAS cancers.

Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies

Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors Combination of Investigational SHP2 Inhibitor and Anti-PD-1 Antibody to be Evaluated in Patients with Solid Tumors

Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor

REDWOOD CITY, Calif., June  18, 2020  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the appointments of Eric T. Schmidt, Ph.D., and Peter Svennilson to its board of directors. Dr. Schmidt and Mr. Svennilson are widely respected executives with extensive Wall Street and financial markets experience in the biopharmaceutical industry. Mr. Svennilson was appointed to fill the vacancy created by the resignation of Larry Lasky, Ph.D., who stepped down from the board of directors and will continue supporting the company as a scientific advisor.

Revolution Medicines Appoints Eric T. Schmidt, Ph.D.

Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors

Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510

Applied Materials

Alibaba

BridgeBio Pharma Inc

Guardant Health Inc

Limelight Networks

Plug Power

Stocks are firing on all cylinders again and have clawed back most of their bear-market losses.

7 Growth Stocks to Buy for Oodles of Upside

Company to Host R&D Update Conference Call Following AACR Meeting Company to Host R&D Update Conference Call Following AACR Meeting

Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million

Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress

Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug Findings Support Plans to Expand Clinical Evaluation of RMC-4630, the Company’s Investigational SHP2 Inhibitor, to Include Combination with Anti-PD-1 Drug

Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models

Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630 Multi-cohort Phase 1/2 Clinical Program Currently Evaluating RMC-4630

Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program

Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations

New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute

Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable

Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.

Investors Scrambled to Buy This Biotech IPO

Amgen

Mirati Therapeutics

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs

REDWOOD CITY, Calif., Feb.  18, 2020  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced the closing of its initial public offering of 16,100,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares of common stock, at a public offering price of $17.00 per share. The gross proceeds from the offering were approximately $273.7 million, before deducting underwriting discounts, commissions and other offering expenses payable by Revolution Medicines. Shares of Revolution Medicines’ common stock began trading on the Nasdaq Global Select Market on February 13, 2020 under the ticker symbol “RVMD”.  All shares in the offering were offered by Revolution Medicines.

Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Revolution Medicines Inc. (NASDAQ: RVMD) entered the market with a bang on Thursday.

Revolution Medicines Enters the Market With a Bang

Shares of Revolution Medicines Inc. , a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a revised range.

News for Revolution Medicines Stock (RVMD)